Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study

Leuk Lymphoma. 2016;57(6):1491-3. doi: 10.3109/10428194.2015.1101096. Epub 2015 Nov 16.

Authors

Aspasia Stamatoullas¹, Imene Rezine¹, Sylvain Mareschal², Anne Lise Ménard¹, Hélène Lanic¹, Marion David³, Sylvie Daliphard⁴, Dominique Penther³, Emilie Lemasle¹, Ophélie Cassuto¹, Pascal Lenain¹, Nathalie Contentin¹, Stéphane Lepretre¹, Fabrice Jardin¹, Christian Bastard³, Hervé Tilly¹

Affiliations

¹ a Hematological Department ;
² b Inserm U 918 ;
³ c Biopathology Department , Centre Henri Becquerel , Rouen , France ;
⁴ d Hematology Laboratory , Centre Hospitalier Universitaire , 1 Rue d'Amiens, 76038 Rouen cedex , France.

PMID: 26430832
DOI: 10.3109/10428194.2015.1101096

No abstract available

Publication types

Letter

MeSH terms

Antibiotic Prophylaxis
Antimetabolites, Antineoplastic / adverse effects
Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / adverse effects
Azacitidine / therapeutic use*
Humans
Hypergammaglobulinemia / complications*
Hypoalbuminemia / complications*
Infections / epidemiology
Infections / etiology*
Myelodysplastic Syndromes / complications*
Myelodysplastic Syndromes / drug therapy*
Retrospective Studies
Risk

Substances

Antimetabolites, Antineoplastic
Azacitidine